MarketCap
Facebook
X
TelegramQuarterly report 2026-Q2
added 05-13-2026
Veru Operating Expenses 2011-2026 | VERU
Annual Operating Expenses Veru
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.5 M | 37.4 M | 107 M | 38.2 M | 53.4 M | 31.4 M | 28.1 M | 29.7 M | 14.6 M | 8.85 M | 12.4 M | 9.2 M | 7.71 M | 9.68 M | 6.57 M | 8.58 M | 8.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 107 M | 6.57 M | 26.3 M |
Quarterly Operating Expenses Veru
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.22 M | 5.42 M | 5.42 M | - | 8.03 M | 9.1 M | 10.9 M | - | 10.7 M | 8.89 M | 8.31 M | - | 19.7 M | 38.5 M | 38.2 M | 68.6 M | 28.9 M | 22.9 M | 16.8 M | 39.2 M | 16.7 M | 12.4 M | 10.1 M | 24.7 M | 7.91 M | 10.1 M | 9.05 M | 20.8 M | 8.41 M | 9.05 M | 5.66 M | 22.7 M | 8.04 M | 5.66 M | 8.75 M | 4.57 M | 3.56 M | 8.75 M | 3.53 M | 2.16 M | 2.38 M | 3.53 M | 3.01 M | 3.36 M | 3.18 M | 3.01 M | 2.37 M | 3.37 M | 2.14 M | 2.37 M | 2.09 M | 533 K | 2.65 M | 2.09 M | 2.37 M | 7.12 M | 2.49 M | 2.37 M | 2.23 M | 4.65 M | 1.36 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 68.6 M | 533 K | 10.5 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
15.5 M | - | - | $ 36.6 M |  USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
381 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
38.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 5.58 | 0.9 % | $ 82.9 M | USA |
 |
Cronos Group
CRON
|
80.2 M | $ 2.74 | 2.43 % | $ 1.05 B |  Canada |
 |
Harrow Health
HROW
|
174 M | $ 32.74 | 6.09 % | $ 1.2 B | USA |
 |
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Organogenesis Holdings
ORGO
|
519 M | $ 2.66 | 4.31 % | $ 337 M | USA |
 |
Pacira BioSciences
PCRX
|
279 M | $ 23.52 | 2.26 % | $ 1.09 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
4.96 B | $ 5.45 | -0.73 % | $ 1.99 B | Canada |
 |
Canopy Growth Corporation
CGC
|
197 M | $ 1.07 | 4.22 % | $ 115 M | Canada |
 |
Tilray
TLRY
|
1.52 B | $ 5.46 | 0.83 % | $ 3.37 B | Canada |
 |
Solid Biosciences
SLDB
|
179 M | $ 6.5 | 0.46 % | $ 569 M | USA |
 |
Aurora Cannabis
ACB
|
183 M | $ 3.57 | 2.88 % | $ 196 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 1.07 | - | $ 1.33 M | USA |
 |
Jupiter Wellness
JUPW
|
39.6 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
41.4 M | $ 1.14 | 6.07 % | $ 109 M | Canada |
 |
cbdMD
YCBD
|
28.9 M | $ 0.77 | 3.13 % | $ 3.1 M | USA |
 |
Evolus
EOLS
|
107 M | $ 6.46 | -2.05 % | $ 416 M | USA |
 |
Sundial Growers
SNDL
|
102 K | $ 1.47 | 1.74 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
558 M | $ 8.37 | 2.39 % | $ 429 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
103 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
133 M | $ 23.41 | -0.15 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
59.1 M | $ 7.23 | 0.84 % | $ 285 M | USA |
 |
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
36.7 M | $ 0.72 | 8.52 % | $ 36 M | USA |
 |
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
7.68 B | $ 16.5 | -0.57 % | $ 19.2 B | USA |
 |
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
31.1 M | $ 0.79 | -3.26 % | $ 28.4 M | USA |
 |
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
3.11 M | $ 0.76 | 1.04 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
7.41 M | $ 2.06 | -0.96 % | $ 23.8 M | USA |